(Q33807859)

29 July 2017

1 reference

title

Bisphosphonates: from grandparents to grandchildren (English)

1 reference

29 July 2017

T Srivastava

1

1 reference

PubMed ID

10618761

29 July 2017

U S Alon

series ordinal

2

1 reference

29 July 2017

1 December 1999

1 reference

29 July 2017

1 reference

29 July 2017

38

1 reference

29 July 2017

12

1 reference

29 July 2017

687-702

1 reference

Diphosphonates and Page's disease of bone.

29 July 2017

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Bisphosphonate effects and the bone remodeling transient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Bisphosphonates: mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

A third-generation bisphosphonate, YM175, inhibits osteoclast formation in murine cocultures by inhibiting proliferation of precursor cells via supporting cell-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Bisphosphonates act on rat bone resorption through the mediation of osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Management of hyperparathyroid patients with grave hypercalcemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

No effect of APD (amino hydroxypropylidene bisphosphonate) on hypercalcemia in patients with renal osteodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Congenital erythropoietic porphyria: skeletal manifestations and effect of pamidronate treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Osteopenia in cerebral palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Familial idiopathic hyperphosphatasia (FIH): response to long-term treatment with pamidronate (APD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Malignant osteopetrosis: hypercalcaemia after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Hypercalcaemia in osteogenesis imperfecta treated with pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

The use of pamidronate in three children with renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Idiopathic infantile arterial calcification in siblings: Radiologic diagnosis and successful treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Idiopathic infantile arterial calcification: unusual features

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Idiopathic infantile arterial calcification: a surviving patient with renal artery stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Diphosphonates in the treatment of myositis ossificans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Use and complications of high-dose disodium etidronate therapy in fibrodysplasia ossificans progressiva

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Esophagitis associated with the use of alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000992289903801201

10.1177/000992289903801201

21 January 2018

Identifiers

DOI

0 references

PubMed ID

10618761

1 reference

PubMed ID

10618761